Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2016

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Deep Vein Thrombosis (DVT) Overview 7
Therapeutics Development 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Overview 8
Pipeline Products for Deep Vein Thrombosis (DVT) - Comparative Analysis 9
Deep Vein Thrombosis (DVT) - Therapeutics under Development by Companies 10
Deep Vein Thrombosis (DVT) - Therapeutics under Investigation by Universities/Institutes 11
Deep Vein Thrombosis (DVT) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Deep Vein Thrombosis (DVT) - Products under Development by Companies 15
Deep Vein Thrombosis (DVT) - Products under Investigation by Universities/Institutes 16
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development 17
3SBio Inc. 17
Dong-A Socio Holdings Co. Ltd. 18
F. Hoffmann-La Roche Ltd. 19
Generex Biotechnology Corporation 20
Laboratorios Farmaceuticos Rovi, S.A. 21
Pharmathen Pharmaceuticals S.A. 22
Deep Vein Thrombosis (DVT) - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ARC-15105 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CM-20201 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
enoxaparin sodium biosimilar - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
enoxaparin sodium biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
enoxaparin sodium biosimilar - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
fondaparinux sodium - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
STP-023725 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TRX-1 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Deep Vein Thrombosis (DVT) - Dormant Projects 42
Deep Vein Thrombosis (DVT) - Discontinued Products 43
Deep Vein Thrombosis (DVT) - Product Development Milestones 44
Featured News & Press Releases 44
Aug 22, 2016: New Real-World Evidence on Venous and Arterial Blood Clot Management including Bayer's Xarelto Accepted for Presentation at ESC Congress 2016 44
May 18, 2016: Janssen to Present Data on Rivaroxaban at the 2016 American Society of Clinical Oncology Annual Meeting 47
Apr 25, 2016: Patent Term for Rivaroxaban Extended in US 48
Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 48
Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 49
Dec 07, 2015: Real-World Data Confirms Safety and Efficacy Profile of XARELTO, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis 50
Nov 30, 2015: New Data from Bayer's Portfolio in Thrombosis to be Presented at ASH 2015 51
Nov 06, 2015: Important Global Data from XARELTO EXPLORER Cardiovascular Research Program Highlighted in 17 Presentations at the American Heart Association Scientific Sessions 2015 51
Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 53
May 04, 2015: Bayer's Xarelto Approved in China for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and for the Treatment of Deep Vein Thrombosis 54
Apr 07, 2015: Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents 55
Mar 30, 2015: New Study Shows Reduced Hospital Admissions and Costs for Deep Vein Thrombosis Patients Treated with XARELTO Compared to Traditional Therapy, With No Difference in Subsequent Hospital Visits 55
Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 57
Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 58
Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2016 8
Number of Products under Development for Deep Vein Thrombosis (DVT) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc., H2 2016 17
Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 18
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corporation, H2 2016 20
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2016 21
Deep Vein Thrombosis (DVT) - Pipeline by Pharmathen Pharmaceuticals S.A., H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2016 42
Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2016 43 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy